Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 369Neoplasms 253Carcinoma, Non-Small-Cell Lung 224Prostatic Neoplasms 192Lung Neoplasms 140Colorectal Neoplasms 137Neoplasm Metastasis 132Pancreatic Neoplasms 131Leukemia, Myeloid, Acute 126Multiple Myeloma 122Lymphoma 114Carcinoma, Hepatocellular 111Ovarian Neoplasms 98Melanoma 97Recurrence 93Leukemia 88Head and Neck Neoplasms 88Leukemia, Lymphocytic, Chronic, B-Cell 86Brain Neoplasms 86Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Glioblastoma 77Lymphoma, Non-Hodgkin 73Squamous Cell Carcinoma of Head and Neck 71Lymphoma, Follicular 70Lymphoma, Large B-Cell, Diffuse 66Colonic Neoplasms 66Carcinoma, Renal Cell 61Hematologic Neoplasms 59Sarcoma 55Glioma 53

Interventions

Nivolumab 1ADI PEG20 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Interventional × Resectable Hepatocellular Carcinoma × Clear all
NCT04965714 2023-02-16

Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Gastrointestinal

Resectable Hepatocellular Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡